{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:30:06Z","timestamp":1792402206868,"version":"4.4.0"},"reference-count":48,"publisher":"American Academy of Pediatrics (AAP)","issue":"Supplement_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:p>Acne vulgaris is an extraordinarily common skin condition in adolescents. The mainstays of acne treatment have remained largely unchanged over recent years. In the context of increasing antibiotic resistance worldwide, there is a global movement away from antibiotic monotherapy toward their more restrictive use. Classically reserved for nodulocystic acne, isotretinoin has become the drug of choice by dermatologists for moderate to severe acne. Given the virtually ubiquitous nature of acne in teenagers, there remains an appreciable need for novel therapies. In this article, we will cover the currently used acne treatments, evaluate the issues and data supporting their use, explore the issues of compliance and the mental health implications of acne care, and recommend directions for the field of acne management in adolescents in the years ahead.<\/jats:p>","DOI":"10.1542\/peds.2019-2056l","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T13:25:17Z","timestamp":1588339517000},"page":"S225-S230","source":"Crossref","is-referenced-by-count":147,"title":["Current Issues in the Treatment of Acne Vulgaris"],"prefix":"10.1542","volume":"145","author":[{"given":"Kaiane A.","family":"Habeshian","sequence":"first","affiliation":[{"name":"Division of Dermatology, Children\u2019s National Hospital, Washington, District of Columbia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard A.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Johns Hopkins Hospital, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"issue":"3","key":"2021120906502283700_B1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bjd.12149","article-title":"Epidemiology of acne vulgaris","volume":"168","author":"Bhate","year":"2013","journal-title":"Br J Dermatol"},{"issue":"7","key":"2021120906502283700_B2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/ced.13919","article-title":"The mental health burden in acne vulgaris and rosacea: an analysis of the US National Inpatient Sample","volume":"44","author":"Singam","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"2021120906502283700_B3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1067\/mjd.2003.618","article-title":"Management of acne: a report from a Global Alliance to Improve Outcomes in Acne","volume":"49","author":"Gollnick","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2021120906502283700_B4","first-page":"18","article-title":"Psychosocial impact of postinflammatory hyperpigmentation in patients with acne vulgaris","volume":"10","author":"Darji","year":"2017","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"2021120906502283700_B5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/pde.12802","article-title":"Psychodermatologic effects of atopic dermatitis and acne: a review on self-esteem and identity","volume":"33","author":"Nguyen","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"2021120906502283700_B6","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2147\/PPA.S117437","article-title":"Interventions to increase adherence to acne treatment","volume":"10","author":"Moradi Tuchayi","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2021120906502283700_B7","article-title":"Factors affecting adherence and patient satisfaction with treatment: a cross-sectional study of 500 patients with acne vulgaris [published online ahead of print May 28, 2019]","author":"Hayran","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"2021120906502283700_B8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jamadermatol.2014.5254","article-title":"Frequency of primary nonadherence to acne treatment","volume":"151","author":"Anderson","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2021120906502283700_B9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","article-title":"Guidelines of care for the management of acne vulgaris","volume":"74","author":"Zaenglein","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2021120906502283700_B10","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/jamadermatol.2017.6144","article-title":"The role of the physician in patient perceptions of barriers to primary adherence with acne medications","volume":"154","author":"Ryskina","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"6","key":"2021120906502283700_B11","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jaad.2012.02.031","article-title":"Do automated text messages increase adherence to acne therapy? Results of a randomized, controlled trial","volume":"67","author":"Boker","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2021120906502283700_B12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaad.2017.09.078","article-title":"Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne","volume":"78","author":"Thiboutot","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2021120906502283700_B13","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1473-3099(15)00527-7","article-title":"Systematic review of antibiotic resistance in acne: an increasing topical and oral threat","volume":"16","author":"Walsh","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"2021120906502283700_B14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jaad.2018.09.055","article-title":"Approaches to limit systemic antibiotic use in acne: systemic alternatives, emerging topical therapies, dietary modification, and laser and light-based treatments","volume":"80","author":"Barbieri","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2021120906502283700_B15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jamadermatol.2017.1297","article-title":"Antibiotic resistance in acne treatment","volume":"153","author":"Adler","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"10","key":"2021120906502283700_B16","first-page":"5","article-title":"Benzoyl peroxide: enhancing antibiotic efficacy in acne management","volume":"15","author":"Dutil","year":"2010","journal-title":"Skin Therapy Lett"},{"issue":"3","key":"2021120906502283700_B17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s13555-017-0185-2","article-title":"Why topical retinoids are mainstay of therapy for acne","volume":"7","author":"Leyden","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"2021120906502283700_B18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clinthera.2005.02.009","article-title":"Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment","volume":"27","author":"Leyden","year":"2005","journal-title":"Clin Ther"},{"issue":"2","key":"2021120906502283700_B19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40257-018-0352-y","article-title":"Prevention and reduction of atrophic acne scars with adapalene 0.3%\/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6-month randomized, vehicle-controlled trial using intra-individual comparison","volume":"19","author":"Dr\u00e9no","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"2021120906502283700_B20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-019-00423-z","article-title":"Topical retinoids in acne vulgaris: a systematic review","volume":"20","author":"Kolli","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"2021120906502283700_B21","unstructured":"US Food and Drug Administration. FDA approves Differin Gel 0.1% for over-the-counter use to treat acne. 2016. Available at: https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm510362.htm. Accessed April 5, 2019"},{"issue":"7","key":"2021120906502283700_B22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0149-2918(02)80023-6","article-title":"A randomized, double-blind comparison of a clindamycin phosphate\/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris","volume":"24","author":"Cunliffe","year":"2002","journal-title":"Clin Ther"},{"issue":"3","key":"2021120906502283700_B23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1046\/j.1365-2133.2003.05067.x","article-title":"Antibiotic-resistant acne: lessons from Europe","volume":"148","author":"Ross","year":"2003","journal-title":"Br J Dermatol"},{"issue":"2","key":"2021120906502283700_B24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2133.2005.06614.x","article-title":"Treatment of acne with topical antibiotics: lessons from clinical studies","volume":"153","author":"Simonart","year":"2005","journal-title":"Br J Dermatol"},{"issue":"8","key":"2021120906502283700_B25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1001\/archdermatol.2011.67","article-title":"Antibiotics, acne, and Staphylococcus aureus colonization","volume":"147","author":"Fanelli","year":"2011","journal-title":"Arch Dermatol"},{"key":"2021120906502283700_B26","unstructured":"US Food and Drug Administration. Drug approval package: Seysara (sarecycline). 2018. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/209521Orig1s000TOC.cfm. Accessed April 5, 2019"},{"issue":"11","key":"2021120906502283700_B27","first-page":"1358","article-title":"Antibiotic resistance: shifting the paradigm in topical acne treatment","volume":"13","author":"Andriessen","year":"2014","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"2021120906502283700_B28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1529-8019.2009.01261.x","article-title":"Should dermatologists prescribe hormonal contraceptives for acne?","volume":"22","author":"Harper","year":"2009","journal-title":"Dermatol Ther"},{"issue":"7","key":"2021120906502283700_B29","first-page":"CD004425","article-title":"Combined oral contraceptive pills for treatment of acne","author":"Arowojolu","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2021120906502283700_B30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jaad.2017.12.051","article-title":"Incidence of androgenic dermatologic side effects following placement of a levonorgestrel intrauterine device for menorrhagia: a survey-based study","volume":"79","author":"Lullo","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2021120906502283700_B31","first-page":"670","article-title":"Hormonal contraceptives and acne: a retrospective analysis of 2147 patients","volume":"15","author":"Lortscher","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"9","key":"2021120906502283700_B32","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamadermatol.2015.34","article-title":"Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne","volume":"151","author":"Plovanich","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2021120906502283700_B33","doi-asserted-by":"crossref","first-page":"e4447","DOI":"10.1136\/bmj.e4447","article-title":"Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study","volume":"345","author":"Mackenzie","year":"2012","journal-title":"BMJ"},{"issue":"6","key":"2021120906502283700_B34","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","article-title":"Spironolactone use and the risk of breast and gynecologic cancers","volume":"37","author":"Biggar","year":"2013","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"2021120906502283700_B35","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaad.2016.12.028","article-title":"Isotretinoin treatment for acne and risk of depression: a systematic review and meta-analysis [published correction appears in J Am Acad Dermatol. 2018;78(2):431]","volume":"76","author":"Huang","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"2021120906502283700_B36","first-page":"CD009435","article-title":"Oral isotretinoin for acne","author":"Costa","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"2021120906502283700_B37","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamadermatol.2013.6862","article-title":"Women\u2019s experiences with isotretinoin risk reduction counseling","volume":"150","author":"Werner","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2021120906502283700_B38","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1001\/jamadermatol.2014.4171","article-title":"Promoting safe use of isotretinoin by increasing contraceptive knowledge","volume":"151","author":"Werner","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"10","key":"2021120906502283700_B39","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamadermatol.2019.1388","article-title":"US Food and Drug Administration reports of pregnancy and pregnancy-related adverse events associated with isotretinoin","volume":"155","author":"Tkachenko","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"10","key":"2021120906502283700_B40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1001\/jamadermatol.2019.1247","article-title":"Early strides for necessary data-driven improvement in iPLEDGE","volume":"155","author":"Nagler","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"3","key":"2021120906502283700_B41","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jaad.2018.02.045","article-title":"Dermatologic care for lesbian, gay, bisexual, and transgender persons: epidemiology, screening, and disease prevention","volume":"80","author":"Yeung","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2021120906502283700_B42","unstructured":"American Medical Association. Gender identity inclusion and accountability in REMS D-100.968. 2017. Available at: https:\/\/policysearch.ama-assn.org\/policyfinder\/detail\/REMS?uri=%2FAMADoc%2Fdirectives.xml-D-100.968.xml. Accessed August 20, 2019"},{"key":"2021120906502283700_B43","unstructured":"American Academy of Dermatology. Position statement on isotretinoin. 2018. Available at: https:\/\/www.aad.org\/Forms\/Policies\/Uploads\/PS\/ps-isotretinoin.pdf. Accessed August 20, 2019"},{"issue":"2","key":"2021120906502283700_B44","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1111\/ajd.12909","article-title":"The role of nutrition in inflammatory pilosebaceous disorders: implication of the skin-gut axis","volume":"60","author":"Maarouf","year":"2019","journal-title":"Australas J Dermatol"},{"issue":"1\u20132","key":"2021120906502283700_B45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.31128\/AJGP-06-18-4609","article-title":"General practitioners\u2019 attitudes towards acne management: psychological morbidity and the need for collaboration","volume":"48","author":"Zureigat","year":"2019","journal-title":"Aust J Gen Pract"},{"issue":"6","key":"2021120906502283700_B46","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamadermatol.2016.0183","article-title":"Modeling the effect of shared care to optimize acne referrals from primary care clinicians to dermatologists","volume":"152","author":"Liu","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"8","key":"2021120906502283700_B47","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/ced.13971","article-title":"Depression and the dermatologist: a critical analysis of contemporary isotretinoin prescribing practices","volume":"44","author":"Daunton","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"2021120906502283700_B48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaad.2016.02.1148","article-title":"Depression screening using health questionnaires in patients receiving oral isotretinoin for acne vulgaris","volume":"75","author":"Schrom","year":"2016","journal-title":"J Am Acad Dermatol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/145\/Supplement_2\/S225\/906620\/peds_20192056l.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/145\/Supplement_2\/S225\/906620\/peds_20192056l.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T01:09:35Z","timestamp":1639098575000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/145\/Supplement_2\/S225\/34371\/Current-Issues-in-the-Treatment-of-Acne-Vulgaris"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":48,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2020,5,1]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2019-2056l","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}